CD33 is a member of the immunoglobulin superfamily of molecules. It is a myeloid differentiation marker and it may play a role in inflammation and immune response. Although CD33 is expressed on myeloid progenitor cells, it is not expressed on hematopoietic stem cells.1

CD33 is expressed on nearly all acute myeloid leukemia (AML) cells, making it an ideal target for therapy.1,2 In studies of pediatric AML, the presence of cancer cells expressing high levels of CD33 was associated with poor prognosis, including shorter disease-free intervals and lower overall survival.1

Learn more about modalities targeting CD33:
BiTE® technology, HLE BiTE® technology.

Search our clinical trials.

CD: cluster of differentiation.


1. Laszlo GS, Estey EH, Walter RB. Blood Rev. 2014;28(4):143-153. 2. Krupka C, Kufer P, Kischel R, et al. Blood. 2014;123(3):356-365.